Global Sickle Cell Anemia Therapeutics Market Strategic Research Report

Scope of the Report

The global Sickle Cell Anemia Therapeutics market size is predicted to grow from US$ 4,757 million in 2025 to US$ 11,350 million in 2032; it is expected to grow at a CAGR of 13.4% from 2026 to 2032.

Sickle cell disease (SCD) is a chronic, inherited blood disorder caused by a mutation in the beta-globin gene, leading to the production of abnormal hemoglobin called sickle hemoglobin (HbS). Under low-oxygen conditions, HbS polymerizes, causing red blood cells to assume a rigid, sickle shape. These deformed cells are prone to hemolysis and can block blood vessels, resulting in pain, anemia, and organ damage. Therapeutic approaches include pharmacological treatments (e.g., hydroxyurea, L-glutamine), gene therapy, hematopoietic stem cell transplantation, and supportive care.

Global Sickle Cell Anemia Therapeutics key players include Emmaus Medical, Theravia, Gamida Cell, GlycoMimetics, etc. Americas is the largest market, with a share about 55%, followed by Europe, and Middle East & Africa, both have a share over 35 percent. In terms of product, Blood Transfusion is the largest segment, with a share over 35%. And in terms of application, the largest application is Child, followed by Adult.The therapeutic landscape for sickle cell disease is rapidly evolving, with major pharmaceutical players (e.g., Pfizer, Novartis, Novo Nordisk) investing alongside specialized biotech firms (e.g., Bluebird Bio, CRISPR Therapeutics, Imara, Emmaus Medical). Approved treatments range from small-molecule agents like L-glutamine (Emmaus) to gene-based curative approaches such as Bluebird’s Zynteglo and CRISPR/Vertex’s Casgevy, marking a shift toward durable, potentially one-time interventions. Future development will prioritize expanding patient access to gene therapies, addressing long-term safety, and improving conditioning regimens for stem cell transplantation. Novel approaches, including anti-adhesion therapies (GlycoMimetics), nitric oxide modulators (Prolong), and macrophage-targeted solutions (Modus), are diversifying the pipeline. With ongoing clinical innovation and supportive regulatory momentum, the field is transitioning from symptomatic relief to functional cures, especially for underserved global populations.

This report presents a comprehensive overview of the global Sickle Cell Anemia Therapeutics market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Blood Transfusion
• Pharmacotherapy
• Bone Marrow Transplant

Segment by players, this report covers

• Emmaus Medical
• Theravia
• Pfizer
• Novartis
• Bluebird Bio
• Novo Nordisk
• Gamida Cell
• CRISPR Therapeutics
• GlycoMimetics
• Prolong Pharmaceuticals
• Modus Therapeutics
• Sangamo Biosciences
• Bioverativ
• Imara
• Ironwood Pharmaceuticals

Segment by Application

• Child
• Adult

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Sickle Cell Anemia Therapeutics market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Child, Adult evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact